Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
招募中
1
100.0%
暂无批准数据
- The OPTIMA trial involving over 4,400 patients demonstrated that the Prosigna genomic test can identify hormone receptor-positive breast cancer patients who can safely avoid chemotherapy without compromising outcomes. - Patients with low Prosigna scores showed nearly identical survival rates whether they received chemotherapy or hormone therapy alone, with 93.6% versus 94.8% remaining cancer-free after five years. - The findings could transform treatment decisions for the most common breast cancer subtype, potentially sparing thousands of patients from chemotherapy's severe side effects while reducing healthcare costs. - Researchers believe this represents a major milestone in precision breast oncology, providing Level 1A evidence for genomic-guided treatment decisions in early-stage breast cancer care.
- Alamar Biosciences closed an oversubscribed convertible notes financing exceeding $50 million, with T. Rowe Price Investment Management and Braidwell LP joining as new investors alongside existing backers. - The company appointed Dr. Stephen Williams as Chief Scientific Officer, bringing over 30 years of precision medicine experience from roles at Pfizer, Standard BioTools, and SomaLogic. - Rebecca Chambers and Dr. Frank Witney joined the board of directors to strengthen leadership as the company advances its NULISA technology and ARGO HT System for ultra-high sensitivity proteomics. - The funding will support commercial advancement of Alamar's precision proteomics platform designed to enable early disease detection and address limitations of existing technologies.
- The prospective BALANCE trial demonstrates that the PAM50 molecular signature can predict which men with recurrent prostate cancer will benefit from apalutamide hormone therapy combined with salvage radiation therapy. - Among 127 men with luminal B molecular subtype tumors, 72% taking apalutamide avoided biochemical failure compared to 54% in the placebo group, while non-luminal B patients showed no treatment difference. - This represents the first prospective validation of a predictive biomarker in non-metastatic prostate cancer, potentially transforming personalized treatment decisions for recurrent disease.
- Veracyte will present the first prospective validation data for a molecular signature predicting hormone therapy benefit in men with recurrent prostate cancer at ASTRO 2025. - The findings were derived using Veracyte's Decipher GRID research tool, which contains more than 200,000 whole-transcriptome profiles from patients with urologic cancers. - Nine Decipher-focused abstracts, including six podium presentations, will be presented at the conference, examining adverse molecular features in prostate cancer. - The Decipher Prostate test is a 22-gene genomic classifier that has achieved "Level I" evidence status and inclusion in NCCN Guidelines for prostate cancer.
- The Decipher Prostate Genomic Classifier test successfully identified metastatic prostate cancer patients who benefit from docetaxel chemotherapy, showing a 36% reduction in death risk for high-scoring patients. - Among 832 metastatic prostate cancer patients in the STAMPEDE trial, those with high Decipher scores had significant survival improvement with docetaxel, while lower-scoring patients showed minimal benefit. - The 22-gene test becomes the first molecular diagnostic with randomized trial evidence to guide chemotherapy decisions in metastatic prostate cancer, potentially sparing patients from unnecessary treatment side effects. - Additional analysis revealed that combining Decipher scores with PTEN status further refined patient selection, with high Decipher/PTEN inactive tumors showing 45% reduction in death hazards with docetaxel.
- Champions Oncology has appointed Rob Brainin as Chief Executive Officer effective August 25, 2025, succeeding Dr. Ronnie Morris who will transition to Executive Chair. - Brainin brings over 25 years of life sciences experience, most recently serving as Chief Business Officer at Veracyte and previously as CEO of Genuity Science. - The leadership change positions Champions to expand beyond core CRO services into robust data offerings and advance its discovery therapeutics subsidiary, Corellia AI. - Dr. Morris, who led the company since 2017, will remain actively involved in strategic initiatives while supporting the leadership transition.
- Gustave Roussy has initiated UMBRELLA, a groundbreaking phase III trial that personalizes post-treatment cancer monitoring based on minimal residual disease (MRD) detected through blood-based circulating tumor DNA analysis. - The trial will evaluate two strategies: pre-emptive immunotherapy (tislelizumab) for MRD-positive patients and reduced follow-up schedules for MRD-negative patients with non-metastatic lung, colorectal, pancreatic, and soft tissue sarcomas. - UMBRELLA represents the first French multi-cancer trial using MRD status for therapeutic stratification, aiming to enroll over 700 patients across 10-11 centers in a collaborative effort involving Veracyte, IntegraGen, and BeiGene.
- Veracyte has launched the Decipher Prostate Metastatic Genomic Classifier, making it the only gene expression test covered by Medicare across all prostate cancer risk levels. - The 22-gene test helps identify which metastatic prostate cancer patients will likely benefit from available treatments, potentially sparing others from unnecessary toxic side effects. - Clinical validity has been demonstrated in multiple prospective Phase 3 studies, building on the test's established utility in localized prostate cancer where it achieved "Level I" evidence status in NCCN Guidelines.
- New data from the TOMBOLA trial demonstrates Veracyte's whole-genome sequencing-based MRD testing platform detected muscle-invasive bladder cancer with higher specificity than ddPCR-based methods. - The Veracyte platform identified cancer recurrence a median of 93 days earlier than standard imaging, potentially enabling earlier intervention for patients with muscle-invasive bladder cancer. - Veracyte plans to launch its first MRD test for muscle-invasive bladder cancer in the first half of 2026, expanding its portfolio of urologic cancer diagnostics.
• Bio-Rad Laboratories has entered a binding agreement to acquire Stilla Technologies, enhancing its digital PCR capabilities with Stilla's next-generation systems for applications including oncology diagnostics and infectious disease testing. • The acquisition, expected to close by Q3 2025, aims to serve the full spectrum of digital PCR applications and strengthen Bio-Rad's position in the rapidly growing global digital PCR market, projected to reach $3.68 billion by 2032. • Despite a recent 9.5% stock decline following the announcement, analysts remain optimistic about Bio-Rad's growth potential, with consensus estimates indicating a 12.2% earnings increase for fiscal 2025.
